Citigroup Maintains Buy on Immunovant, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $28 to $33.
August 11, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a Buy rating on Immunovant and raises the price target from $28 to $33, which could lead to a positive impact on the stock.
The raised price target by Citigroup indicates a positive outlook for Immunovant. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100